Posts Archive

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma iMMagine-1 NCT05396885: Phase 2: Study of...

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma This research study involves the study of TriPRIL CAR T Cells for treating...

CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...

NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients This is...

UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...

MagnetisMM-3 NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma Relapsed & Refractory...

NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma This is a...

NCT04430894: Phase 2: KRDI in Transplant-Eligible MM KRDI in Transplant-Eligible MM This research study is testing the efficacy of an...

KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...

NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors A Phase...

NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Dara-KPd This research study is studying the...

NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM...

CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...

NCT04155749: Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Master Protocol for the Phase 1 Study...

AMG 420 To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous...

CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...

CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...